Evidence map›Paper›PMID 28822989›Full record

ArticleBiomolecules & therapeutics2018

Cellular Prion Protein Enhances Drug Resistance of Colorectal Cancer Cells via Regulation of a Survival Signal Pathway.

Jun Hee Lee, Chul Won Yun, Sang Hun Lee

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

  1. PrPInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer.International journal of molecular sciences · 2023
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Observational
  16. The Cellular Prion Protein: A Promising Therapeutic Target for Cancer.International journal of molecular sciences · 2020
    Review
  17. Review
  18. Review
  19. Review
  20. Prion Protein in Glioblastoma Multiforme.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Jun Hee LeeDepartment of Pharmacology and Toxicology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA.
Chul Won YunMedical Science Research Institute, Soonchunhyang University Seoul Hospital, Seoul 04401, Republic of Korea.
Sang Hun LeeMedical Science Research Institute, Soonchunhyang University Seoul Hospital, Seoul 04401, Republic of Korea.
Soonchunhyang University Hospital · KRUniversity of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-cancer drug resistance is a major problem in colorectal cancer (CRC) research. Although several studies have revealed the mechanism of cancer drug resistance, molecular targets for chemotherapeutic combinations remain elusive. To address this issue, we focused on the expression of cellular prion protein (PrP

Indexed as

5-fluorouracilAnticancerColorectal cancerDrug resistancePrion protein

Identifiers

PMID28822989
PMCPMC5933899
OpenAlexW2746542326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.